Dr. Buchholz is Assistant Professor, Department of Neurosurgery, University of Virginia Health System, Spine Center, 415 Ray C. Hunt Dr, Suite 3100, Charlottesville, VA 22903, E-mail: firstname.lastname@example.org; Dr. Quinn is Assistant Professor, Department of Neurological Surgery, University of Texas Health Science Center, Houston, Texas; Dr. Buell is Resident Physician, Dr. Yen is Associate Professor, Dr. Shaffrey is Professor of Neurosurgery and Orthopedic Surgery, Duke Medical Center, Durham, North Carolina; Dr. Smith is Professor, Department of Neurosurgery, University of Virginia Health System, Charlottesville, Virginia; and Dr. Haid is Neurosurgeon, Atlanta Brain and Spine Care, Atlanta, Georgia.
The authors, faculty, and staff in a position to control the content of this CME activity, and their spouses/life partners (if any), have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations relevant to this CME activity.
The authors have disclosed that investigational use of recombinant human bone morphogenetic protein-2 is discussed in this article. Please consult product labeling for approved uses.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the newsletter's website (www.contempneurosurg.com).
Lippincott Continuing Medical Education Institute, Inc, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Lippincott Continuing Medical Education Institute, Inc, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article and complete the quiz and evaluation on the enclosed form, answering at least 70% of the quiz questions correctly. This activity expires on February 14, 2021.